Ricardo Gonzalez Balboa Appointed as General Manager of Eisai Laboratorios, S. de R.L. de C.V.
Will Lead Commercial Strategy for Eisai's Subsidiary in Mexico

WOODCLIFF LAKE, N.J., May 16, 2013 /PRNewswire/ -- Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announces the appointment of Ricardo Gonzalez Balboa to the position of General Manager, Eisai Laboratorios, S. de R.L. de C.V. (Eisai Mexico), a direct subsidiary of Eisai Inc. In this position, Mr. Gonzalez Balboa will further develop and implement the company's commercial strategy in Mexico.

(Photo: http://photos.prnewswire.com/prnh/20130516/NY11800 )

(Logo: http://photos.prnewswire.com/prnh/20120413/MM87168LOGO )

Since its establishment in 2011, Eisai Mexico has filed several products with the Federal Commission for the Protection Against Sanitary Risk (COFEPRIS) for regulatory review. Eisai Mexico is focusing on further development of its operations in preparation for the introduction of these products, supporting Eisai's human health care (hhc) mission to satisfy unmet medical needs and contribute to the health and well-being of people worldwide.

Under Mr. Gonzalez Balboa's leadership, Eisai Mexico will continue to establish productive relationships with key constituents in Mexico's healthcare system and ensure compliance of sales and marketing practices with all applicable regulations and laws.

"We are very pleased to have Ricardo on the ground in Mexico to help build Eisai's capabilities there, and bring our company's products to patients in the region," said Douglas Calandra, Vice President of Latin America, Eisai Inc. "Ricardo possesses the business competencies critical for success in this role, and also has a passion for creating patient value. We are confident that he is the right leader to build our Mexican organization, and to help further our human health care mission within this important country."

Mr. Gonzalez Balboa comes to Eisai from Bayer Health Care, where he headed the Specialty Medicine and Institutional Business for the company's Mexican operations. In addition to leading marketing strategy and promotion for several products there, he oversaw access and pharmaco-economics functions. 

Prior to Bayer, Mr. Gonzalez Balboa spent ten years with Roche in Mexico, where he attained roles of increasing responsibility in various functions, including oncology, metabolism, respiratory, hematology, business development and market research. His most recent role there was oncology director. Prior to Roche, he held financial analyst and business planning positions with Bristol-Myers Squibb's Mexican operations.

Eisai Laboratorios, S. de R.L. de C.V.

Eisai Laboratorios, S. de R.L. de C.V. (Eisai Mexico), a wholly owned subsidiary of Eisai Inc., is Eisai's commercial operation in Mexico. The company was established in 2011 and is based in Mexico City.

Eisai Inc.

At Eisai Inc., human health care is our goal. We give our first thoughts to patients and their families, and helping to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., our passionate commitment to patient care is the driving force behind our efforts to help address unmet medical needs. We are a fully integrated pharmaceutical business with discovery, clinical, manufacturing and marketing capabilities. Our key areas of commercial focus include oncology and specialty care (Alzheimer's disease, epilepsy and metabolic disorders). To learn more about Eisai Inc., please visit us at www.eisai.com/US

Eisai Inc. has affiliates that are part of a global product creation organization that includes R&D facilities in Massachusetts, New Jersey, North Carolina and Pennsylvania, as well as a global demand chain organization that includes manufacturing facilities in Maryland and North Carolina. Eisai's global areas of R&D focus include neuroscience; oncology; metabolic disorders; vascular, inflammatory and immunological reaction; and antibody-based programs.

Eisai Co., Ltd.

Eisai Co., Ltd. is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system.

Media Inquiries

Investor Inquiries

Lisa Wolfe

Alex Scott

Eisai Inc.

Eisai Inc.






SOURCE Eisai Inc.

Type Press Release

Date Released May 16, 2013

May 9, 2022

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Michel Vounatsos, "Biogen") announced today...

Apr 26, 2022

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") today announced an article about long-term health outcomes of its investigational anti-amyloid-beta (Aβ) protofibril antibody...

Apr 7, 2022

Eisai stands with people living with Alzheimer’s disease (AD), health care professionals and other members of our AD community. We respect that the Centers for Medicare and Medicaid Services...

Alerts - Release page
* Required Fields